When Antibiotics Stop Working: Why Phage Therapy Matters for Life Sciences Risk

For decades, antibiotics have been one of modern medicine's greatest success stories. They transformed once-deadly infections into treatable conditions, making routine surgeries, organ transplants, cancer therapies, and intensive care medicine possible. But a growing threat is challenging that foundation: antimicrobial resistance (AMR).

As bacteria evolve resistance to existing treatments, healthcare, biotechnology, regulatory, investment, and insurance stakeholders are increasingly focused on finding new approaches to combat difficult-to-treat infections. One area attracting renewed attention is phage therapy, a treatment strategy that uses naturally occurring viruses called bacteriophages to target harmful bacteria. Although still emerging, phage therapy sits at the intersection of healthcare innovation, biotechnology investment, regulatory strategy, and life sciences risk management.

Antibiotic Resistance: A Growing Global Challenge

AMR occurs when bacteria and other microbes evolve and no longer respond to medications designed to kill them. Naturally occurring genetic changes contribute to resistance, while antibiotic overuse and misuse in both humans and animals have accelerated the problem.

As resistance spreads, infections become increasingly difficult to treat. Patients often require longer hospital stays, more intensive treatments, additional diagnostic testing, and alternative therapies that may be more costly or less effective.

The consequences extend far beyond healthcare. A widely cited global analysis estimated that bacterial antimicrobial resistance was associated with approximately 4.95 million deaths worldwide in 2019, including roughly 1.27 million deaths directly attributable to resistant infections. More recent World Health Organization (WHO) materials continue to identify AMR as one of the most significant global health threats facing modern medicine. Under a high-impact World Bank scenario, unchecked AMR could reduce annual global GDP by as much as 3.8% by 2050 and push as many as 28 million people into poverty.

The stakes extend far beyond the treatment of common infections. Modern cancer care depends heavily on effective antibiotics because chemotherapy can suppress the immune system, leaving patients vulnerable to bacterial infections. Organ transplantation, advanced cell and gene therapies, cardiac surgery, joint replacement procedures, and countless other medical interventions also rely on effective antimicrobial therapies to prevent or manage serious infections.

Without effective antibiotics, many of the advances that define modern healthcare become substantially more difficult and riskier to deliver.

Why the Antibiotic Innovation Model Is Under Strain

Paradoxically, the need for new antibiotics has never been greater, yet the economics of antibiotic development remain challenging.

Unlike therapies for chronic diseases that may be taken for months or years, antibiotics are generally prescribed for short periods. In addition, antibiotic stewardship programs appropriately limit the use of newly approved antibiotics to slow the development of resistance. While these practices are medically necessary, they can make it difficult for developers to generate returns sufficient to support continued research and development.

The result is a well-documented disconnect between public health need and commercial viability. As policymakers and healthcare leaders continue to search for solutions to that challenge, interest in alternative antibacterial technologies has grown.

Phage Therapy: An Old Idea Experiencing a Revival

Bacteriophages, commonly referred to as phages, are viruses that infect bacteria. Scientists have known about phages for more than a century, and phage-based treatments were explored before antibiotics became widely available.

Traditional antibiotics often work broadly across multiple bacterial targets. Phages, by contrast, can be selected to target specific bacterial strains. This precision raises the possibility of eliminating harmful bacteria while preserving much of the body's beneficial microbiome.

Although phage therapy largely disappeared from mainstream Western medicine following the antibiotic revolution of the 1940s, research and clinical use continued in parts of Eastern Europe and the former Soviet Union. Rising rates of AMR have helped renew interest globally, particularly as advances in genomics, microbial science, and synthetic biology have improved researchers' ability to identify, characterize, and engineer phages.

Why Investors and Biotech Companies Are Paying Attention

The resurgence of phage therapy is being driven by advances across several scientific disciplines, including genomics, precision medicine, synthetic biology, and bioengineering.

Researchers are developing phage libraries, engineered phages, and combination approaches that use both phages and conventional antibiotics. Investigators are also exploring potential applications in multidrug-resistant infections, chronic wound infections, medical device-associated infections, and other difficult-to-treat bacterial conditions.

For investors and life sciences companies, the unmet clinical need is significant. At the same time, the path to commercialization remains complex. Companies operating in this space are pursuing a variety of business models, including standardized phage products, engineered-phage platforms, and personalized treatment approaches tailored to individual patients and infections.

While the opportunity is promising, the scientific, manufacturing, and regulatory challenges remain substantial.

Key Scientific, Regulatory, and Commercial Challenges 

Despite growing enthusiasm, phage therapy is not yet a mainstream medical solution.

Regulation remains one of the most significant hurdles. In the United States, bacteriophage products intended to treat or prevent disease are generally regulated as biological products and drugs. Clinical investigations typically proceed through investigational pathways that require developers to demonstrate product quality, safety, and effectiveness. Personalized or rapidly adaptable phage approaches can raise additional questions regarding product characterization, manufacturing consistency, quality control, and evidentiary standards. 

Manufacturing also presents challenges. Producing biologic therapies consistently, safely, and at scale requires sophisticated quality systems, significant technical expertise, and robust controls throughout the production process.

Clinical evidence continues to evolve as well. Although case reports, compassionate-use experiences, and early clinical studies have produced encouraging findings, many researchers believe larger clinical trials and clearer development pathways will be necessary before phage therapy achieves broader adoption.

These challenges are familiar to participants throughout the life sciences ecosystem, including biotechnology companies, investors, regulators, healthcare providers, and insurers.

What This Means for Life Sciences Risk

For life sciences companies, phage therapy illustrates both the promise and complexity of emerging biologic platforms. Phage therapy is also notable because it challenges traditional assumptions that therapies can be manufactured, approved, and distributed as identical products for all patients.

Organizations pursuing these technologies may face evolving questions involving clinical trial design, manufacturing controls, regulatory strategy, product quality, intellectual property, commercialization, and product liability. As development programs advance, the industry will likely continue to refine approaches to personalized therapies, adaptive treatment platforms, and biologic manufacturing oversight. Similarly, as phage-based products advance, stakeholders will likely continue to evaluate risks associated with clinical trials, manufacturing quality, regulatory uncertainty, professional liability, and product performance.

For insurers and risk professionals, the field is noteworthy because it combines many traditional biotechnology risks with novel considerations associated with highly targeted or individualized therapies. The evolution of phage therapy may offer insight into how future precision biologics are developed, regulated, and insured. The emergence of highly targeted biologic therapies may also raise novel questions regarding underwriting, claims management, and the allocation of risk across the product lifecycle.

Looking Ahead

Phage therapy is unlikely to replace antibiotics entirely. Instead, many experts envision a future in which physicians have a broader set of tools available to combat increasingly complex bacterial threats.

Combination strategies that use both antibiotics and phages may ultimately prove particularly valuable in certain settings. More broadly, the renewed interest in phage therapy reflects a larger trend across healthcare: the movement toward precision medicine, targeted biologics, and individualized treatment strategies enabled by advances in genomics, artificial intelligence, and synthetic biology.

Conclusion

Antimicrobial resistance is no longer simply a scientific concern. It is a healthcare, economic, regulatory, and risk-management challenge with implications for healthcare systems, employers, investors, life sciences companies, and insurers alike.

Phage therapy remains an emerging field, and significant scientific, regulatory, manufacturing, and commercial questions remain unresolved. Yet its growing momentum demonstrates how urgently the healthcare and life sciences sectors are searching for new solutions to address resistant infections and why risk professionals should continue to watch this space closely.

Authored by Lisa Krist, Berkley Life Sciences, VP, Chief Customer Focus Officer